Please login to the form below

Not currently logged in
Email:
Password:

Nucala

This page shows the latest Nucala news and features for those working in and with pharma, biotech and healthcare.

Cancer drugs and China sustain AZ’s return to growth

Cancer drugs and China sustain AZ’s return to growth

with rivals such as GlaxoSmithKline’s Nucala (mepolizumab), which was first to market and made $729m last year.

Latest news

  • Advair generics and acquisitions to hit GSK in 2019 Advair generics and acquisitions to hit GSK in 2019

    These include three-drug COPD product Trelegy which realised £156m ($202m) for the year and Nucala, rising 64% to £563m ($729m) in the year.

  • AstraZeneca wins NICE backing for asthma injection AstraZeneca wins NICE backing for asthma injection

    choice.”. Boysen even pointed out that AZ's drug could have some advantages over GSK’s Nucala and Teva’s Cinqaero. ... This differs from Nucala and Teva, which both require a treatment schedule of every four weeks.

  • Dupixent helps put Sanofi back on growth track Dupixent helps put Sanofi back on growth track

    They think the asthma indication could be worth $2.5bn on its own, although it’s a crowded market with GlaxoSmithKline’s Nucala (mepolizumab), Teva’s Cinqair (reslizumab) and AstraZeneca’s

  • Boehringer’s Corsico to be new GSK drug dev leader Boehringer’s Corsico to be new GSK drug dev leader

    However the company has just received bad news from the FDA, the US regulator refusing to approval a licence extension for its respiratory drug Nucala into COPD, citing i nsufficient efficacy

  • FDA rejects GSK’s Nucala for COPD FDA rejects GSK’s Nucala for COPD

    the agency reviewers who suggested that GSK had failed to provide sufficient evidence that Nucala was effective in preventing COPD exacerbations. ... Meanwhile, Nucala isn’t the first drug in the IL-5 inhibitor class to run into trouble in COPD.

More from news
Approximately 15 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Its revenues grew by a further 9% last year. “A large percentage of this growth was driven by Ellipta, but Nucala - a biologic approved for asthma and COPD - also played its

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics